Stock PLTX PELOTON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Peloton Therapeutics, Inc.

Equities

PLTX

US70614L1044

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Merck & Co., Inc. completed the acquisition of Peloton Therapeutics, Inc. from The Column Group LLC.
CI
Peloton Therapeutics, Inc. has withdrawn its IPO in the amount of $159.375 million.
CI
Merck & Co., Inc. signed a definitive agreement to acquire Peloton Therapeutics, Inc. from The Column Group LLC for $2.2 billion.
CI
Peloton Therapeutics Announces Board Changes
CI
Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million.
CI
Peloton Therapeutics To Seek Acquisitions
CI
Peloton Therapeutics, Inc. announced that it has received $150 million in funding from a group of investors
CI
Peloton Therapeutics Announces Appointment of John Moore as General Counsel and Corporate Secretary
CI
Peloton Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer
CI
Peloton Therapeutics Initiates Phase 2 Trial of OralHIF-2a Inhibitor PT2977 for Treatment of Von Hippel-Lindau Disease-Associated Kidney Cancer
CI
Peloton Therapeutics, Inc. Announces Board Changes
CI
Peloton Therapeutics, Inc. Announces Results from A Phase 1 Study Evaluating PT2385 in Patients with Advanced Kidney Cancer
CI
Peloton Therapeutics, Inc. Initiates Patient Dosing in Phase 2 Study of PT2385 for Von Hippel-Lindau Disease-Associated Kidney Cancer
CI
Peloton Therapeutics, Inc. Appoints Mohammad Hirmand as Chief Medical Officer, Effective from May 1, 2017
CI
Peloton Therapeutics, Inc. announced that it has received $74.6 million in funding from Foresite Capital Management, LLC, Remeditex Ventures, LLC, The Column Group LLC, Topspin Partners LBO, LP, Nextech Invest Ltd., Tichenor Ventures, LLC
CI
Peloton Therapeutics, Inc. announced that it expects to receive $52.4 million in funding from Foresite Capital Management, LLC, Remeditex Ventures, LLC, The Column Group LLC, Topspin Partners LBO, LP, Nextech Invest Ltd., Tichenor Ventures, LLC
CI
Peloton Therapeutics, Inc. Presents Clinical Data on First-In-Class Oral HIF-2a Inhibitor in Patients with Advanced Kidney Cancer
CI
Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2a Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PLTX Stock
  4. News Peloton Therapeutics, Inc.